^
BIOMARKER:

CD20 positive

i
Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Entrez ID:
Related biomarkers:
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
CD20 positive
CLL
rituximab
Sensitive: A1 - Approval
CD20 positive
NHL
rituximab
Sensitive: A1 - Approval
CD20 positive
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Follicular Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
NHL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
ALL
rituximab
Sensitive: A2 - Guideline
CD20 positive
NHL
rituximab + copanlisib
Sensitive: B - Late Trials
CD20 positive
Lymphoma
rituximab + copanlisib
Sensitive: B - Late Trials
CD20 positive
Follicular Lymphoma
Truxima (rituximab biosimilar)
Sensitive: C1 - Off-label
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: C1 - Off-label
CD20 positive
Diffuse Large B Cell Lymphoma
GEN3013
Sensitive: C2 – Inclusion Criteria
CD20 positive
Follicular Lymphoma
GEN3013
Sensitive: C2 – Inclusion Criteria
CD20 positive
Lymphoma
copanlisib
Sensitive: C2 – Inclusion Criteria
CD20 positive
CLL
FCR
Sensitive: C3 – Early Trials
CD20 positive
Diffuse Large B Cell Lymphoma
venetoclax + obinutuzumab
Sensitive: C3 – Early Trials
CD20 positive
NHL
rituximab + ALX148
Sensitive: C3 – Early Trials
CD20 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
CD20 positive
NHL
rituximab + PF-05082566
Sensitive: C3 – Early Trials
CD20 positive
Follicular Lymphoma
MB-106
Sensitive: C3 – Early Trials
CD20 positive
B Acute Lymphoblastic Leukemia
ofatumumab
Sensitive: C3 – Early Trials
CD20 positive
Mantle Cell Lymphoma
GEN3013
Sensitive: C3 – Early Trials